The growth arrest-specific gene 7 (GAS7), a member of the growth-arrest-specific family, encodes three protein isoforms (GAS7A, GAS7B, and GAS7C) and plays a potential role in lung cancer as a tumor suppressor gene. In the present study, we found low endogenous expressions of GAS7C mRNA and protein in hepatocellular carcinoma (HCC) cell lines compared with normal liver cells, and that there was a distinct increase of GAS7C expression in HCC cells treated with oxaliplatin. CCK8, apoptosis, and Transwell migration assays showed that cell proliferation and motility of HepG2 and MHCC-97 H cells were inhibited by oxaliplatin, while apoptosis was increased. Interestingly, western blot analysis showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of proteins involved in the fibronectin/integrin/ FAK pathway, such as FAK, in both HCC cell lines. In addition, ectopically overexpressed GAS7C obviously inhibited cell proliferation and cell motility. Flow cytometry results showed that overexpression of GAS7C induced apoptosis of HepG2 and MHCC-97 H cells. We further confirmed the correlation between GAS7C and the N-WASP/FAK/F-actin pathway by q-PCR and western blot analysis of in GAS7C-overexpressing HepG2 and MHCC-97 H cells. Inhibition of GAS7C substantially reversed the anti-cancer effect of oxaliplatin and blocked the activity of the N-WASP/FAK/F-actin pathway. Taken together, our results showed that oxaliplatin inhibits HCC cell proliferation and migration ability by up-regulating GAS7C and activating the N-WASP/FAK/F-actin pathway.
Introduction
Hepatocellular carcinoma (HCC) is one of the most fatal and common solid cancers globally, and is the second leading cause of death from malignancy following lung cancer [1, 2] . Oxaliplatin, a platinumbased anti-neoplastic agent, is a chemotherapeutic that has been used as a component of a mixed solution containing epirubicin, oxaliplatin, mitomycin, and lipiodol, which participates in transcatheter arterial chemoembolization (TACE) for HCC in China [3] . A randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/ leucovorin versus doxorubicin as palliative chemotherapy was performed in patients with advanced HCC from mainland China, Taipei of China, Korea, and Thailand, which showed that the regimen of oxaliplatin plus fluorouracil/leucovorin improved the overall survival and progression-free survival, although the primary endpoint was not met [4] .
Growth arrest-specific gene 7 (GAS7), a gene originally discovered from growth-arrested mouse NIH3T3 fibroblast cells cultured without serum by using a retrovirus-based gene search strategy, is abundantly expressed in the brain and is essential for the outgrowth of neurites from cultured cerebellar neurons [5, 6] . As a member of the Pombe Cdc 15 homology (PCH) protein family, GAS7 is predominantly expressed in neurons and is evolutionarily conserved in mammals [7] . Orthologs of the GAS7 gene have been cloned and identified from tissues of mouse, rats, humans, and other mammalian cells [8] . Regardless of the species, GAS7 gene encoding three protein isoforms (GAS7A, GAS7B, and GAS7C) has been transcribed through alternative splicing [8, 9] . The GAS7 protein consists of a series of different functional domains: Src homology 3 domain (SH3), WW domain, and FES-CIP4 homology (FCH) domain. SH3 domains are able to change the subcellular localization of the bound protein and are associated with signaling pathways that regulate the cytoskeleton [10] . Among human GAS7 isoforms, only GAS7C possesses a Src homology 3 domain [11] .
It has been shown that GAS7 may be involved in the promotion, maintenance, maturation, and morphological differentiation of cerebellar neurons [12] . A functional link between human GAS7 and chondrogenic differentiation of human mesenchymal stem cells has been found [13] . A significant association between the GAS7 gene and clinical outcome in medulloblastoma samples was observed, showing that GAS7 can be used as a marker of mature neuronal cells with potential antitumorigenic activity in neuronal tumors [14] . The GAS7 gene is expressed at low levels in patients diagnosed with primary lung squamous cell carcinoma (SCC), suggesting an important role of GAS7 in lung SCC tumorigenesis [15] . Collectively, these findings suggest that the GAS7 gene plays a widespread role in cell differentiation, oncogenesis, and cancer therapy.
Neural-Wiskott Aldrich syndrome protein (N-WASP), a key regulator of Arp2/3 complex-mediated actin polymerization, has been found to be associated with a functional WW domain of the GAS7 protein [16] . It has been shown that GAS7 co-localizes and physically interacts with N-WASP, mediated by its WW domain during neuronal maturation/differentiation [17] . Activation of the FAK/N-WASP pathway is known to be involved in cell migration [18] . FAK signaling proteins and actin dynamic-associated proteins are recruited with integrin receptors to induce microfilament rearrangement and cell migration. In addition, clinical data suggested that 23.6% of lung cancer patients had low expression of GAS7C, which correlated with poorer overall survival and prognosis in lung cancer, suggesting that low GAS7C expression is correlated with lung cancer metastasis [2] . As a metastasis-suppressor gene, GAS7C regulates cancer cell motility through the N-WASP/ FAK/F-actin pathway, which has been confirmed after a series of molecular analyses [16] .
In the present study, we observed that both the mRNA and protein levels of GAS7C were significantly increased in HepG2 and MHCC-97 H cells treated with a low dose of oxaliplatin. However, the relationship between GAS7C and low-dose oxaliplatin treatment of HCC cells has not been demonstrated in human cancers. We overexpressed the GAS7C gene in both HepG2 and MHCC-97 H cells or silenced GAS7C expression in both HepG2 and MHCC-97 H cells, followed by treatment with oxaliplatin, and found that the GAS7C gene is involved in controlling growth arrest, apoptosis, and migration of HCC cells in response to oxaliplatin through the N-WASP/FAK/F-actin pathway.
Materials and Methods

Cell culture and reagents
Human normal liver cell line (L02) and HCC cell lines (HepG2, MHCC-97 L, and MHCC-97 H) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and were cultured in high-glucose Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, USA) supplemented with 10% fetal bovine serum (Gibco), 100 U/ml penicillin, and 100 U/ml streptomycin (Amresco, Solon, USA). Oxaliplatin was purchased from Sigma (St Louis, USA).
Cell counting kit-8 assay
Cells (3 × 10 3 /well) were seeded into wells of 96-well plates with oxaliplatin at a final concentration of 1 μM and incubated at 37°C and 5% CO 2 for 24 h. Then, cells were incubated in drug-free medium. CCK-8 kit (Tokyo, Japan) was used to assess cell viability after treatment with oxaliplatin. Briefly, 10 μl of CCK-8 solution was added to each well and incubated for 30 min, then the absorbance at 450 nm was determined using a microplate reader (Thermo Fisher Scientific, Waltham, USA).
Matrigel invasion assay
The migration and invasion ability of oxaliplatin-treated cells, GAS7C-overexpressing cells, and GAS7C-silenced cells were performed by Transwell assays. After treatment, cells (3 × 10 5 ) were seeded into the upper chamber of a Transwell (Falcon, BD Labware, USA) with DMEM containing 10% fetal bovine serum in the lower chamber. After 24 h, non-invading cells in the upper chamber were removed by scrubbing with a cotton-tipped swab. Afterwards, the cells were fixed with 4% paraformaldehyde for 20 min and stained with 0.2% crystal violet (SigmaAldrich) for 10 min. Six fields were photographed for each chamber using an inverted microscope and camera (MOTIC, Xiamen, China).
Real-time PCR
Total RNA was isolated using the Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer's recommendations. One microgram total RNA was reverse-transcribed to synthesize cDNA according to the manufacturer's protocols. Q-PCR was performed for GAPDH, GAS7C, N-WASP, and FAK with specific primers listed in Table 1 . The 2 −ΔΔCT method was used to quantify the relative expression of these genes.
Western blot analysis
Cells treated with oxaliplatin were lysed in an ice-cold buffer (150 mM NaCl, 0.02% NaN 3 , 0.1% SDS, 50 mM Tris-HCl, pH 8.0, 100 μg/ml phenylmethylsulfonyl fluoride, 1 μg/ml aprotinin, and 1% Triton) for 30 min. The protein concentration of collected lysates was measured by BCA protein assay kit (Pierce, Rockford, USA). Then, 50 μg lysates were separated by 12% SDS-PAGE and transferred onto PVDF membranes (Millipore, Billerica, USA). The PVDF membranes were blocked in TBST containing 2% BSA for 1 h, and incubated with primary antibodies (Santa Cruz Biotech, Santa Cruz, USA) specific for GAS7C (1:1500), GAPDH (1:2000), 
Construction of GAS7C-expressing plasmid
The pEGFP-C and pEGFP-GAS7C plasmids were purchased from OriGene Company (Rockville, USA). Plasmid transfection was performed using a Trans-Messenger Reagent kit (Qiagen, Valencia, USA) according to the manufacturer's recommendations.
Oligo RNAs and transfection
The specific RNAi sequence for human GAS7C (GAS7C-siRNA) and negative control (control-siRNA) were chemically synthesized by GenePharma Biocompany (Shanghai, China). The RNA sequence for GAS7C-siRNA was 5′-GCUCGGCGGGAAUGCAGGCUGCG CU-3′. Approximately 1 × 10 6 cells/well were cultured in 12-well plates and transfected with either GAS7C-siRNA (100 nM) or control-siRNA (100 nM) using RNAiMAX transfection reagent (Invitrogen) according to the manufacturer's protocols. Forty-eight hours after transfection, the cells were collected for subsequent experiments.
Flow cytometry analysis
For Annexin V-FITC apoptosis detection, HepG2 and MHCC-97 H cells were harvested after treatment, washed, and double stained with Annexin-V/PI (MULTI SCIENCE, Hangzhou, China) according to the manufacturer's instructions. All samples were then subject to FACS flow cytometry, and data were analyzed using Cell Quest software (Becton Dickinson, Franklin Lakes, USA).
Statistical analysis
Data are presented as the mean ± standard error of the mean (SEM) of at least three independent experiments. Student's t-test was used to assess differences between groups. A value of P < 0.05 was considered statistically significant.
Results
GAS7C is expressed at low levels in human HCC cell lines
Since the expression levels of GAS7C in human normal liver and human HCC cell lines have never been reported, the mRNA expressions of GAS7C in L02, HepG2, MHCC-97 L, and MHCC-97 H cell lines were first examined. As shown in Fig. 1A , the GAS7C mRNA levels of HCC cell lines (HepG2, MHCC-97 L, and MHCC-97 H) were lower than that of the normal liver cell line (L02), and the levels of GAS7C were the lowest in MHCC-97 H cells. Based on western blot analysis of protein extracted from human normal liver and HCC cell lines, the expression levels of GAS7C protein varied among these cell types and corresponded to the mRNA expression level. The protein level of GAS7C was also the lowest in the MHCC-97 H cells (Fig. 1B) .
Oxaliplatin inhibits HCC cell proliferation and migration, and induces apoptosis via the up-regulation of GAS7C and N-WASP to impair FAK/F-actin signals
To investigate the role of GAS7C in the response of HCC cells to oxaliplatin, the cell lines with the lowest expressions of GAS7C, MHCC-97 H, and HepG2 cells were selected. CCK8, cell apoptotic analysis, and Transwell migration assays were carried out to examine the proliferation, apoptosis, and motility of MHCC-97 H and HepG2 cells in response to oxaliplatin. After continuous exposure to a low dose of oxaliplatin, cell proliferation, apoptosis, and cell motility of both MHCC-97 H and HepG2 cells were inhibited by oxaliplatin ( Fig. 2A-C) . Interestingly, it was found that the mRNA level of GAS7C was significantly increased after oxaliplatin treatment (Fig. 2D) . Western blot analysis showed that the protein level of GAS7C was also significantly increased (Fig. 2G) .
To further explore the molecular mechanism of this inactivation, Western blot analysis was performed to determine the association between the N-WASP/FAK/F-actin pathway and oxaliplatin-induced GAS7C protein expression. As shown in Fig 2E,F , the mRNA level of N-WASP was increased, while that of FAK was decreased in response to oxaliplatin. Western blotting results showed that treatment with oxaliplatin increased GAS7C and N-WASP protein levels and decreased the levels of fibronectin/integrin/FAK pathway proteins, such as FAK (Fig. 2G) . Therefore, up-regulation of GAS7C and inhibition of the fibronectin/integrin/FAK pathway were involved in oxaliplatin-induced inhibition of proliferation and migration ability.
GAS7C overexpression inhibits cell proliferation and migration, and induces apoptosis of HCC cells via the N-WASP/FAK/F-actin pathway
To confirm the hypothesis that GAS7 plays a role in oxaliplatininduced inhibition of HCC cell proliferation and migration, GAS7C in both MHCC-97 H and HepG2 cells was overexpressed. Overexpression of GAS7C obviously inhibited cell proliferation and motility of both MHCC-97 H and HepG2 cells (Fig. 3A,C) . To investigate the effect of GAS7C overexpression on the apoptosis of MHCC-97 H and HepG2 cells, each cell line was stained with propidium iodide (PI) and Annexin V-FITC. Flow cytometry results showed that the percentage of apoptotic cells overexpressing GAS7C was about 2-fold greater than that of vector control cells in both HCC cell lines (Fig. 3B) . Our results showed that oxaliplatin inhibited the proliferation and migration ability via GAS7C upregulation and the N-WASP/FAK/F-actin pathway; thus, we hypothesize that overexpression of GAS7C inhibits cell proliferation and migration ability through the N-WASP/FAK/F-actin pathway. After HCC cells were transfected with pEGFP-GAS7C, the mRNA levels of GAS7C and N-WASP were significantly increased (Fig. 3D,E) . Accordingly, the protein levels of both GAS7C and N-WASP were also significantly increased as shown by western blot analysis (Fig. 3G) . Both the mRNA and protein levels of FAK were decreased as a result of GAS7C overexpression. These results suggest that GAS7C overexpression inhibits cell proliferation and migration of HCC cells via the N-WASP/FAK/F-actin pathway. 
GAS7C knockdown resists the anti-cancer effect of oxaliplatin via GAS7C and the N-WASP/FAK/F-actin pathway
To further address the direct role of GAS7C in the anti-cancer induction of oxaliplatin, MHCC-97 H and HepG2 cells were transfected with GAS7C siRNA, followed by exposure to a low dose of oxaliplatin. As expected, the oxaliplatin-induced inhibition of proliferation, migration, and promotion of apoptosis were reversed because of the knockdown of GAS7C (Fig. 4A-C) . Knockdown of GAS7C consistently and substantially reversed the regulation of GAS7C, N-WASP, and FAK expressions induced by oxaliplatin (Fig. 4D-G) .
Discussion
Due to poor survival statistics and an increasing population with HCV infections and other liver diseases, HCC has become the fifth most common malignant cancer worldwide and the second leading cause of cancer mortality in the Chinese male population [19] . While patients at high risk of HCC can be monitored, <30% of patients with the disease are eligible for liver resection, transplantation, or local ablation [20, 21] . Most patients receive some form of chemotherapy, hoping to prolong life, in response to the high incidence of tumor recurrence and intrahepatic metastasis after surgical resection.
Oxaliplatin is considered as one of the most potentially advantageous cytotoxic drugs available in the treatment of HCC, but the mechanism of drug resistance to oxaliplatin is still unclear [22] . As a third-generation platinum analog, oxaliplatin has attracted much attention due to several potential advantages of the treatment for HCC. Due to its increased cytotoxicity, inhibition of DNA synthesis, and wider spectrum of activity compared with other platinum analogs, oxaliplatin is commonly used as a first-line therapy. In the present study, we reported that cell proliferation and migration ability were inhibited, and the expression of GAS7C was up-regulated, by treatment with a low dose of oxaliplatin. Subsequently, we aimed to clarify the specific molecular mechanisms of HCC cells in response to oxaliplatin. GAS7 is predominantly expressed in the nervous system and is necessary for neurite formation and microfilament organization. GAS7C, a GAS7 gene transcription isoform, is the major alternative isoform in human lung cancer cell lines. In an experimental metastasis animal model, GAS7C overexpression was shown to decrease lung metastases [16] . Previous studies have shown that GAS7 is co-localized to membrane protrusions and directly interacts with N-WASP via the WW-Pro domain [17] . Therefore, we further investigated the association of N-WASP protein with GAS7C in both MHCC-97 H and HepG2 cells treated with oxaliplatin. We found that the protein level of N-WASP was increased but the protein level of FAK was significantly decreased after treatment with a low dose of oxaliplatin. Thus, the N-WASP/ FAK/F-actin pathway may be involved in the oxaliplatin-induced inhibition of HCC cell proliferation and migration ability. Then, the GAS7C gene was ectopically overexpressed to further demonstrate that the important role played by GAS7C in the inhibition of cell proliferation and migration ability is via the N-WASP/FAK/F-actin pathway. Our data showed that GAS7C overexpression inhibits cell proliferation and migration ability, and induces apoptosis in MHCC-97 H and HepG2 cells. Moreover, western blot analysis showed that GAS7C overexpression resulted in significant increase in N-WASP protein levels and inhibition of the FAK/F-actin pathway. We also knocked down GAS7C in MHCC-97 H and HepG2 cells, and then exposed the cells to a low dose of oxaliplatin. Our results showed that silencing GAS7C resists the anti-cancer effect of oxaliplatin and prevents changes in the expressions of GAS7C and key components of the N-WASP/FAK/F-actin pathway. In summary, our findings showed that GAS7C expression in HCC cells is lower than that in normal liver cells. The specific molecular mechanism by which oxaliplatin suppresses human HCC is via GAS7C and the N-WASP/FAK/F-actin pathway. GAS7C may act as a suppressor of tumor metastasis in HCC patients receiving chemotherapy with oxaliplatin, indicating that approaches to stabilize the GAS7C protein are promising in the development of HCC chemotherapeutics. 
